Drug intelligence / Profile preview

AD-223A

Development stage: Phase 3
Lead developer: Addpharma
Modality: Small Molecules

Overview

AD-223A is a small molecule drug developed by Addpharma for the treatment of essential hypertension. It is part of a combination therapy (with AD-223B) that has reached Phase 3 clinical trials. The drug's primary indication is cardiovascular disease, specifically essential hypertension. While the precise mechanism of action and molecular target have not been disclosed in public sources as of June 2025, it does not appear to represent a novel mechanism or modality based on available data[3][4]. Clinical trials have been conducted primarily in Korea and the United States.

Beyond the preview

Go deeper on AD-223A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-223A.

Explore the full profile